151 related articles for article (PubMed ID: 15239804)
1. False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer.
Aguiar-Bujanda D; Bohn-Sarmiento U; Aguiar-Morales J
Breast J; 2004; 10(4):375-6. PubMed ID: 15239804
[No Abstract] [Full Text] [Related]
2. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB
J BUON; 2007; 12(4):487-92. PubMed ID: 18067207
[TBL] [Abstract][Full Text] [Related]
3. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of CA 15-3 serum levels in breast cancer patients.
Skrzydlewski Z; Niklinski J; Kiluk S; Kiluk M; Musiatowicz B; Zaremba E; Skrzydlewska E; Klepacki A
Minerva Chir; 1997 Mar; 52(3):251-4. PubMed ID: 9099053
[TBL] [Abstract][Full Text] [Related]
5. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer].
Feng J; Hu LH; Lu J; Li YR; Xie F
Ai Zheng; 2009 Apr; 28(4):436-40. PubMed ID: 19622308
[TBL] [Abstract][Full Text] [Related]
7. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
[TBL] [Abstract][Full Text] [Related]
8. Ca 15.3 in breast cancer: comparison of two assays and validation in a Mexican population.
Guarner J; Valdivieso E; Quintana A; Frias M; Ramirez T
Arch Med Res; 1997; 28(4):523-6. PubMed ID: 9428577
[TBL] [Abstract][Full Text] [Related]
9. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
[TBL] [Abstract][Full Text] [Related]
10. [Routine use of serial plasmatic CA 15-3 determinations during the follow-up of patients treated for breast cancer. Evaluation as factor of early diagnosis of recurrence].
Chourin S; Veyret C; Chevrier A; Loeb A; Gray C; Basuyau J
Ann Biol Clin (Paris); 2008; 66(4):385-92. PubMed ID: 18725339
[TBL] [Abstract][Full Text] [Related]
11. Midkine in plasma as a novel breast cancer marker.
Ibusuki M; Fujimori H; Yamamoto Y; Ota K; Ueda M; Shinriki S; Taketomi M; Sakuma S; Shinohara M; Iwase H; Ando Y
Cancer Sci; 2009 Sep; 100(9):1735-9. PubMed ID: 19538527
[TBL] [Abstract][Full Text] [Related]
12. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
13. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
[No Abstract] [Full Text] [Related]
14. Late breast cancer recurrence to the uterine cervix with a review of the literature.
Manci N; Marchetti C; Esposito F; Graziano M; Tomao F; Pastore M; Bellati F; Panici PB
Int J Gynecol Pathol; 2008 Jan; 27(1):113-7. PubMed ID: 18156985
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients.
Stieber P; Molina R; Chan DW; Fritsche HA; Beyrau R; Bonfrer JM; Filella X; Gornet TG; Hoff T; Jäger W; van Kamp GJ; Nagel D; Peisker K; Sokoll LJ; Troalen F; Untch M; Domke I
Clin Lab; 2003; 49(1-2):15-24. PubMed ID: 12593471
[TBL] [Abstract][Full Text] [Related]
16. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
[No Abstract] [Full Text] [Related]
17. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
18. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer.
Heinze T; Lichtenegger W
Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor markers in breast cancer.
Tondini C; Hayes DF; Kufe DW
Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
[TBL] [Abstract][Full Text] [Related]
20. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
